Skip to main content
PMC home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1992 Apr;76(4):241–243. doi: 10.1136/bjo.76.4.241

Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial.

Y Ozyazgan 1, S Yurdakul 1, H Yazici 1, B Tüzün 1, A Işçimen 1, Y Tüzün 1, T Aktunç 1, H Pazarli 1, V Hamuryudan 1, A Müftüoğlu 1
PMCID: PMC504238  PMID: 1390495

Abstract

A single masked trial of cyclosporin A 5 mg/kg/day versus monthly 1 g intravenous boluses of cyclophosphamide was conducted among 23 patients with Behçet's syndrome and active, potentially reversible uveitis. The trial was unmasked after a mean of 12 (SD 2) months for the cyclosporin A group (n = 12) and a mean of 10 (SD 3) months for the cyclophosphamide group (n = 11). During the initial 6 months the visual acuity significantly improved (p < 0.001) in the cyclosporin A group whereas this was not observed in the cyclophosphamide group. The subsequent follow-up of patients up to 24 months suggested that the initial improvement in visual acuity with cyclosporin A was not sustained. More extensive and especially long-term studies of cyclosporin A in the uveitis of Behçet's syndrome are warranted.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BenEzra D., Cohen E., Chajek T., Friedman G., Pizanti S., de Courten C., Harris W. Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. Transplant Proc. 1988 Jun;20(3 Suppl 4):136–143. [PubMed] [Google Scholar]
  2. BenEzra D., Cohen E., Rakotomalala M., de Courten C., Harris W., Chajek T., Friedman G., Matamoros N. Treatment of endogenous uveitis with cyclosporine A. Transplant Proc. 1988 Jun;20(3 Suppl 4):122–127. [PubMed] [Google Scholar]
  3. Binder A. I., Graham E. M., Sanders M. D., Dinning W., James D. G., Denman A. M. Cyclosporin A in the treatment of severe Behçet's uveitis. Br J Rheumatol. 1987 Aug;26(4):285–291. doi: 10.1093/rheumatology/26.4.285. [DOI] [PubMed] [Google Scholar]
  4. Kahan B. D. Cyclosporine. N Engl J Med. 1989 Dec 21;321(25):1725–1738. doi: 10.1056/NEJM198912213212507. [DOI] [PubMed] [Google Scholar]
  5. Masuda K., Nakajima A., Urayama A., Nakae K., Kogure M., Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet. 1989 May 20;1(8647):1093–1096. doi: 10.1016/s0140-6736(89)92381-7. [DOI] [PubMed] [Google Scholar]
  6. Müftüoğlu A. U., Pazarli H., Yurdakul S., Yazici H., Ulkü B. Y., Tüzün Y., Serdaroğlu S., Altuğ E., Bahçecioğlu H., Güngen G. Short term cyclosporin A treatment of Behçet's disease. Br J Ophthalmol. 1987 May;71(5):387–390. doi: 10.1136/bjo.71.5.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Nussenblatt R. B., Palestine A. G., Chan C. C., Mochizuki M., Yancey K. Effectiveness of cyclosporin therapy for Behçet's disease. Arthritis Rheum. 1985 Jun;28(6):671–679. doi: 10.1002/art.1780280611. [DOI] [PubMed] [Google Scholar]
  8. Nussenblatt R. B., Palestine A. G., Rook A. H., Scher I., Wacker W. B., Gery I. Treatment of intraocular inflammatory disease with cyclosporin A. Lancet. 1983 Jul 30;2(8344):235–238. doi: 10.1016/s0140-6736(83)90230-1. [DOI] [PubMed] [Google Scholar]
  9. Svenson K., Bohman S. O., Hällgren R. Renal interstitial fibrosis and vascular changes. Occurrence in patients with autoimmune diseases treated with cyclosporine. Arch Intern Med. 1986 Oct;146(10):2007–2010. [PubMed] [Google Scholar]
  10. Tugwell P., Bombardier C., Gent M., Bennett K. J., Bensen W. G., Carette S., Chalmers A., Esdaile J. M., Klinkhoff A. V., Kraag G. R. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet. 1990 May 5;335(8697):1051–1055. doi: 10.1016/0140-6736(90)92630-z. [DOI] [PubMed] [Google Scholar]
  11. Wechsler B., Mertani E. B., le Hoang P., de Groc F., Piette J. C., Beaufils H., Aupetit B., le Minh H., Rottembourg J. Cyclosporin A is effective, but not safe, in the management of Behçet's disease. Arthritis Rheum. 1986 Apr;29(4):574–575. doi: 10.1002/art.1780290420. [DOI] [PubMed] [Google Scholar]
  12. Yazici H., Pazarli H., Barnes C. G., Tüzün Y., Ozyazgan Y., Silman A., Serdaroğlu S., Oğuz V., Yurdakul S., Lovatt G. E. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med. 1990 Feb 1;322(5):281–285. doi: 10.1056/NEJM199002013220501. [DOI] [PubMed] [Google Scholar]
  13. Yazici H., Tüzün Y., Pazarli H., Yurdakul S., Ozyazgan Y., Ozdoğan H., Serdaroğlu S., Ersanli M., Ulkü B. Y., Müftüoğlu A. U. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis. 1984 Dec;43(6):783–789. doi: 10.1136/ard.43.6.783. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES